Share on LinkedInShare on LinkedIn

ARTICLE · 23 APRIL 2012

The Inequitable Conduct Doctrine Lives

On April 9, 2012, a Federal Circuit panel of judges — Linn, Dyk, and Prost — upheld a finding of inequitable conduct from Chief Judge Sleet in the District of Delaware. Aventis Pharma S.A. et al. v. Hospira, Inc. et al., Fed. Cir., No. 2011-1018, 4/9/12.

United StatesIntellectual Property

On April 9, 2012, a Federal Circuit panel of judges — Linn, Dyk, and Prost — upheld a finding of inequitable conduct from Chief Judge Sleet in the District of Delaware. Aventis Pharma S.A. et al. v. Hospira, Inc. et al., Fed. Cir., No. 2011-1018, 4/9/12. The court upheld the district court's finding of inequitable conduct, concluding it was consistent with the Federal Circuit's recent Therasense decision, even though the decision issued after the district court's finding. See Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276,1290 (Fed. Cir. 2011) (en banc).

Therasense rejected the "sliding scale" approach to proving inequitable conduct, required separate materiality and intent inquiries, and set out a "but-for" materiality standard. The Aventis court concluded that because the withheld references rendered the patents invalid, they were necessarily material to patentability under the Therasense standard.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from